132 related articles for article (PubMed ID: 27794568)
1. Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.
Musella A; Vertechy L; Romito A; Marchetti C; Giannini A; Sciuga V; Bracchi C; Tomao F; Di Donato V; De Felice F; Monti M; Muzii L; Benedetti Panici P
Chemotherapy; 2017; 62(2):111-120. PubMed ID: 27794568
[TBL] [Abstract][Full Text] [Related]
2. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
3. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.
Colombo N; Conte PF; Pignata S; Raspagliesi F; Scambia G
Crit Rev Oncol Hematol; 2016 Jan; 97():335-48. PubMed ID: 26555461
[TBL] [Abstract][Full Text] [Related]
5. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
7. Hopes and failures in front-line ovarian cancer therapy.
Tsibulak I; Zeimet AG; Marth C
Crit Rev Oncol Hematol; 2019 Nov; 143():14-19. PubMed ID: 31449982
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Carcinosarcoma of the Fallopian Tube Mimicking Ovarian Cancer: A Case Report and Genetic Analysis.
Kim SW; Kim Y
J Nippon Med Sch; 2021; 88(6):574-578. PubMed ID: 34980744
[TBL] [Abstract][Full Text] [Related]
9. [A Retrospective Case Study of Combination Chemotherapy with Bevacizumab for Recurrent Ovarian Cancer].
Hori K; Tsuruta T; Odani C; Ono H; Ohkubo R; Shimoji K; Murakami J; Nakagawa M; Tashima L; Ito K
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1197-1200. PubMed ID: 27760937
[TBL] [Abstract][Full Text] [Related]
10. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
12. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
14. The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Zhang W; Shen Z; Luo H; Hu X; Zheng L; Zhu X
Curr Drug Targets; 2017; 18(10):1125-1131. PubMed ID: 27138763
[TBL] [Abstract][Full Text] [Related]
15. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
[TBL] [Abstract][Full Text] [Related]
17. Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study.
Tanigawa T; Matoda M; Omi M; Aoki Y; Netsu S; Nomura H; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Takeshima N
Anticancer Res; 2020 Sep; 40(9):5285-5290. PubMed ID: 32878818
[TBL] [Abstract][Full Text] [Related]
18. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
19. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer: relevant therapy, not timing, is paramount.
Morris RT; Monk BJ
Lancet; 2010 Oct; 376(9747):1120-2. PubMed ID: 20888975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
